ational Cancer Research Institute acute myeloid leukaemia and high risk MDS trial 16. A trial for older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome (MDS).

Cardiff University (UK)0 个研究点目标入组 2,247 人开始时间: 2005年10月11日最近更新: 2022年2月7日

适应症

试验速览

•1. They have one of the forms of acute myeloid leukaemia, except acute promyelocytic leukaemia, as defined by the World Health Organisation (WHO) Classification - this can be any type of de novo or secondary AML - or high risk Myelodysplastic Syndrome, defined as greater than 10% marrow blasts (RAEB-2)
•2. They should normally be over the age of 60, but patients under this age are eligible if they are not considered fit for the MRC AML 15 trial
•3. They have given written informed consent

•1. Patients have previously received cytotoxic chemotherapy for AML. (Hydroxyurea, or similar low-dose therapy, to control the white count prior to initiation of intensive therapy is not an exclusion.)
•2. They are in blast transformation of chronic myeloid leukaemia (CML)
•3. They have a concurrent active malignancy
•4. They are pregnant or lactating
•5. Patients with abnormal liver function tests exceeding twice the local upper limit of normal are not eligible for the Mylotarg randomisations
•6. Patients with Acute Promyelocytic Leukaemia

发起方

Cardiff University (UK)